Morphosys

MONJUVI

Manufacturer:

Morphosys

Monjuvi HCPCS:

J9349

HCPCS Code Descriptor:

Injection, tafasitamab-cxix, 2 mg

Category:

J Code

Monjuvi NDCs:

73535-0208-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Monjuvi:

MONJUVI is an Oncology drug manufactured by Morphosys and administered via the Intravenous route of administration. The J Code: J9349 is aligned to the drug MONJUVI.

ACCESS PRICING AND MORE BY REGISTERING

J9349 Added Date:

April 1, 2021

J9349 Effective Date:

April 1, 2021

J9349 Termination Date:

HCPCS Active

Monjuvi billing and coding information can be found through Morphosys at the link below:
Monjuvi patient assistance information can be found through My MISSION Support at the URL: https://www.mymissionsupport.com/
MONJUVI prescribing information can be found at the link below:
Information regarding MONJUVI’s side effects can be found at MedlinePlus